CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

United Therapeutics, Liquidia settle Yutrepia patent litigation, agree to dismiss cases with prejudice

By Public Technologies
  • United Therapeutics reached a settlement with Liquidia to end multiple patent disputes tied to Yutrepia sales and labeling.
  • Liquidia must pay USD 185 million within 30 business days for past PH-ILD sales from June 2, 2025 through execution.
  • Liquidia also agreed to pay USD 145.4 million in two installments due by Jan. 31, 2027 and Apr. 30, 2027.
  • United Therapeutics will pay Liquidia USD 10 million to resolve a separate New Jersey case involving Sandoz and RareGen.
  • Claims against former Liquidia executive Robert Roscigno, as an individual, remain pending and were excluded from the releases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-115723), on October 14, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk